Text Size

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT01580241
First received: April 17, 2012
Last updated: NA
Last verified: April 2012
History: No changes posted
  Purpose

The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1


Condition
Pancreatic Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Oklahoma:

Estimated Enrollment: 100
Study Start Date: August 2011
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Surgery group
Patients with pancreatic cancer who undergo surgical treatment only
Chemotherapy group
Patients with pancreatic cancer who undergo chemotherapy treatment only
Neoadjuvant group
Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
Adjuvant group
Patients with pancreatic cancer who undergo surgery followed by chemotherapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a change in DCAMKl-1 expression.

Criteria

Inclusion Criteria:

  • pancreatic cancer

Exclusion Criteria:

  • age < 18, history of other types of cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01580241

Locations
United States, Oklahoma
Stephensen Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Investigators
Principal Investigator: Courtney Houchen, MD University of Oklahoma
  More Information

No publications provided

Responsible Party: University of Oklahoma
ClinicalTrials.gov Identifier: NCT01580241     History of Changes
Other Study ID Numbers: DCAMKL1 Panc CA pre/post surg
Study First Received: April 17, 2012
Last Updated: April 17, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
 Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 19, 2013